Full-Time

Senior Manager

Drug Product Device Assembly and Packaging, Dap, System User

Updated on 8/21/2026

Deadline 9/30/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Goldsboro, NC, USA

In Person

Full-time on-site in Wilson, North Carolina; frequent travel (>75%) required during design phase until the plant site startup in Wilson, NC.

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Six Sigma

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • A Bachelor’s or higher degree in Life Sciences, Pharmacy, or Engineering is required; a Master’s or higher degree is preferred.
  • A minimum of 8 years of experience in the pharmaceutical industry, with demonstrated technical leadership in sterile Drug Product manufacturing environments
  • A minimum of 3–5 years of hands-on experience serving as a Subject Matter Expert in Device Assembly and Packaging (DAP) for aseptically filled parenteral products
  • Strong working knowledge of aseptic processing principles, contamination control strategies, and sterile manufacturing requirements, including barrier technologies
  • Proficiency with automated, digital, and robotic DAP systems used in sterile Drug Product manufacturing, with the ability to translate technology into compliant and efficient operations
  • Proven experience applying and maintaining cGMP compliance within aseptic DP operations, including participation in regulatory inspections and audit readiness activities
  • Strong analytical and problem-solving skills, with a track record of identifying and implementing practical solutions in complex aseptic manufacturing environments
  • Demonstrated ability to lead cross-functional teams and influence stakeholders across engineering, quality, automation, MSAT, and supply chain organization
  • Lean/Six Sigma certifications
Responsibilities
  • Serve as the Device Assembly and Packaging (DAP) Subject Matter Expert for the design, start‑up, commissioning, qualification, and routine operation of an aseptic Drug Product manufacturing facility
  • Provide technical and operational leadership to ensure DAP processes, equipment, and systems comply with cGMP, aseptic processing requirements, and global regulatory expectations.
  • Author, review, and approve User Requirement Specifications (URS) and ensure alignment with aseptic processing strategy, device assembly needs, packaging requirements, and product quality attributes.
  • Review and approve engineering deliverables across project phases, including Process Flow Diagrams (PFDs), P&IDs, functional design specifications, equipment specifications, automation strategies, and process descriptions specific to DAP and aseptic operations.
  • Act as a key contributor to aseptic processing design, including material and personnel flows, environmental controls, line segregation, barrier/isolator or RABS strategies, and contamination prevention measures related to DAP.
  • Collaborate closely with global parenteral DP sites, engineering partners, quality, automation, MSAT, and supply chain teams to ensure harmonization, best‑practice adoption, and successful project delivery.
  • Develop and implement operator training strategies, including qualification plans, technical training, aseptic behavior training, and knowledge transfer for DAP operations.
  • Review the deliverables from concept refresh, basis-and detailed engineering (e.g.: PFD’s , P&ID’s, process descriptions, functional design specifications, equipment specifications)
  • Writing and/or review of Process Support Operational documentation (Master Batch Records, SOP’s, WI’s)
  • Actively support all commissioning and qualification batches
  • Actively support cycle development, cleaning, and hold time studies
  • Preparation and execution review & approval of validation related qualification documents and the resourcing of execution of associated tasks (water batch, engineering batch, aseptic process simulation, validation batches)
  • The identification of required spare parts in accordance with the approved spare part list for the support systems and liaise with relevant parties for their procurement.
  • Monitoring and ensuring all user requirements are met
  • Lead the development, review, and approval of process support operational documentation, including Master Batch Records (MBRs), Standard Operating Procedures (SOPs), Work Instructions (WIs), and packaging/device assembly instructions.
  • Define spare parts strategies for DAP and associated support systems, ensuring availability, lifecycle management, and alignment with maintenance and reliability plans.
  • Ensure timely and accurate responses to information requests, regulatory questions, and audit inquiries related to DAP and aseptic manufacturing readiness.
  • Execute all responsibilities within approved project timelines and budgets, proactively identifying risks and mitigation strategies to support on‑time facility start‑up and commercialization readiness.
Desired Qualifications
  • Lean/Six Sigma certifications

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales hit $25.3 billion, and guidance rose to $101.1 billion.
  • Tremfya surged 72.5% to $2 billion, proving the immunology replacement strategy works.
  • August 21, 2026 TECVAYLI-daratumumab approval and MONARCH QUEST 3 clearance expand pipelines.

What critics are saying

  • July 2026 talc settlement needs 95% claimant approval; failure reopens 76,000 claims.
  • Stelara biosimilars keep crushing legacy revenue, and replacement drugs must sustain 2027 growth.
  • MedTech growth lagged Q2 expectations; Intuitive Surgical and Medtronic intensify hospital-buying competition.

What makes Johnson & Johnson unique

  • J&J spans pharmaceuticals, MedTech, and cash-generating scale after Kenvue’s 2023 spinout.
  • Tremfya, Darzalex, Carvykti, and Tecvayli offset Stelara’s 55% Q2 decline.
  • AAA balance sheet and 64-year dividend streak signal resilience through patent cliffs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.

Yahoo Finance
Aug 21st, 2026
J&J's TECVAYLI plus daratumumab approved in Europe for relapsed/refractory multiple myeloma

The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.

Yahoo Finance
Aug 20th, 2026
J&J CEO signals double-digit growth by decade's end on new drug launches

Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.

Yahoo Finance
Aug 19th, 2026
Johnson & Johnson rises 57% in 12 months with near-zero correlation to S&P 500

Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.

Highly Capitalized
Aug 19th, 2026
J&J leads Delix's $85M Series C with right of first negotiation on neuroplasticity drug

Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.